Asia-Pacific Oral Anti-Diabetic Drug Market

Asia-Pacific Oral Anti-Diabetic Drug Market Analysis

The Asia-Pacific Oral Anti-Diabetic Drug Market size is estimated at USD 26.16 billion in 2025, and is expected to reach USD 30.47 billion by 2030, at a CAGR of 3.1% during the forecast period (2025-2030).

The Asia-Pacific market for oral anti-diabetic drugs is poised for substantial growth, driven by an aging demographic and escalating diabetes rates. Factors such as heightened stress, sedentary lifestyles, smoking, and excessive alcohol consumption are primary contributors to the rising prevalence of diabetes, leading to elevated blood sugar levels.

The region's escalating diabetes rates are a key driver for the growing demand for oral anti-diabetic medications. For instance, projections from IDF indicate that the number of individuals with diabetes in Southeast Asia is set to surge by 68%, reaching around 152 million by 2045. Additionally, the diabetes prevalence rate is expected to surge by 30%, reaching 11.3% in 2045. Moreover, health-related expenditures for diabetes are expected to rise from USD 17,675.4 million in 2030 to USD 21,200.0 million in 2045. This surge in health-related spending, coupled with the climbing diabetes prevalence, is set to underpin the market's expansion.

Advancements in drug delivery technologies, particularly in oral formats, are poised to propel market growth further. For instance, in May 2024, an international team led by Australian researchers introduced a nanotechnology-based system. This innovation paves the way for a future where individuals with diabetes could potentially consume oral insulin. The researchers highlight that this new form of insulin could be ingested via a tablet or even concealed within a piece of chocolate, offering a more palatable option, especially for elderly diabetic patients averse to injections.

The Asia-Pacific oral anti-diabetic drug market is progressing significantly. The rising prevalence of diabetes and advancements in drug delivery technologies will continue to drive demand and innovation. The market is expected to benefit from rising health-related expenditures and the development of more accessible and user-friendly medication formats.

Asia-Pacific Oral Anti-Diabetic Drug Market Trends

Biguanide Segment is Estimated To witness Significant Growth Over the Forecast Period

The biguanide segment was expected to witness significant growth in 2023 owing to increased regulatory approvals and financial ease for increasing the accessibility of affordable drugs.

Metformin, a biguanide, is primarily used to manage type 2 diabetes. It is also prescribed off-label for conditions like insulin resistance. Since its introduction, metformin has successfully treated a significant number of patients. Endorsed as a first-line prescription by IDF, it boasts a commendable risk/benefit profile.

Given its track record, metformin is the most prescribed oral anti-diabetic globally, accounting for 45-50% of all prescriptions and benefiting over 150 million individuals annually. Its dominance is attributed to a combination of factors, including a well-established safety profile, robust clinical efficacy, high patient adherence, affordability, and widespread availability.

Regulatory endorsements play a pivotal role in bolstering market growth. For instance, in June 2023, the US FDA greenlit Jardiance (empagliflozin) and Synjardy (empagliflozin with metformin) for children aged 10 and above with type 2 diabetes, marking a significant stride in pediatric diabetes treatment.

Similarly, in February 2024, Canada's Health Minister announced the government's progress toward a universal pharmacare program. This initiative, once agreed upon with the provinces, will ensure that Canadians, especially diabetic people, have access to primary diabetes treatments, notably metformin, at an annual cost of around CAD 100 (USD 73). Other common medications for type 2 diabetes, like sulfonylureas and SGLT-2 inhibitors, can range from CAD 100 (USD 73) to over CAD 1,000 (USD 733.5) annually. By enhancing affordability, the initiative aims to not only improve the health of people with diabetes but also stimulate market growth.

The biguanide segment, led by metformin, dominates the North American oral anti-diabetic drugs market. The combination of clinical efficacy, affordability, and strong regulatory support ensures its sustained prominence and growth in the market.

China is Expected to Hold a Significant Market Share

China's oral anti-diabetic drug market is surging, driven by a rising diabetic population. With its population size, the nation has become an attractive opportunity for global pharmaceutical players for their product launches. For instance, in June 2023, China's NMPA approved AstraZeneca's Xigduo XR, a once-daily fixed-dose combination containing dapagliflozin and metformin hydrochloride. This approval was specifically for treating adults with type-2 diabetes (T2D) as an adjunct to diet and exercise aimed at enhancing glycaemic control.

Moreover, increasing focus on diabetic drug development in the Chinese market is set to propel market growth. For instance, in May 2024, Innovent Biologics Inc. announced encouraging outcomes from the Phase 3 clinical trial (DREAMS-2) evaluating mazdutide. This drug is a dual agonist targeting the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR); it showcased efficacy in Chinese subjects with type 2 diabetes (T2D).

The combination of a growing diabetic population and increased drug development activities positions China as a significant player in the Asia-Pacific oral anti-diabetic drug market. The country's strategic importance is expected to continue attracting major pharmaceutical companies, further driving market growth.

Asia-Pacific Oral Anti-Diabetic Drug Industry Overview

The Asia-Pacific oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

Asia-Pacific Oral Anti-Diabetic Drug Market Leaders

Asia-Pacific Oral Anti-Diabetic Drug Market News

• May 2024: Chinese regulators approved Eli Lilly and Company's diabetes drug, Tirzepatide, setting the stage for a competition with Novo Nordisk. Novo Nordisk had secured approval for its flagship diabetes drug, Ozempic, in the vast Asian market in 2021.
• October 2023: Glenmark Pharmaceuticals unveiled a novel triple-fixed-dose combination (FDC) drug for diabetes treatment. Its offering, Zita, combines Teneligliptin, Dapagliflozin, and Metformin.